This is the 1st CCSG competitive renewal of the Dan L. Duncan Cancer Center (DLDCC) at Baylor College of Medicine (BCM) in Houston. BCM is located in the Texas Medical Center (TMC), the largest medical center in the country, and Houston is the 4th largest city with a very diverse population. The DLDCC is a matrix Cancer Center with BCM as the lead scientific partner with three hospital affiliates, Texas Children's, the DeBakey Veterans Affairs Medical Center, and Ben Taub General Hospital, as formal clinical partners. The Center was established in 2002 and received NCI designation in July of 2007 and has since made significant progress strengthening its scientific research programs, taking into consideration the prior review and recommendations from our EAB. 37 new cancer faculty have been recruited to the DLDCC which now has 350 formal members, and our cancer-relevant peer reviewed research funding now exceeds $122 million (22% increase), with more than $36 million coming from the NCI. Several high-impact research accomplishments have been made by members, several with the potential to reduce cancer mortality. The DLDCC comprises 7 research programs: Cancer Biology, Viral and Molecular Oncogenesis, Nuclear Receptors, Breast Cancer, Cancer Cell and Gene Therapy, Cancer Prevention and Population Science, and Pediatric Cancer. Investments exceeding $10 million have strengthened the scientific resources, which offer leading technologies and expertise to members. CTSU has been significantly enhanced and accruals to clinical trials have increased over 40%. Accrual of racial and ethnic minorities continues to be outstanding. The Office of Outreach and Health Disparities, using tools developed from NCI funding, disseminates new information to the community, especially the underserved. In this renewal, we ask for increased funding for our 10 Shared Resources, 3 developing resources, and other activities important to our mission and goals, as well as consideration for comprehensive designation according to NCI guidelines.

Public Health Relevance

The investments made by the NCI, combined with the support of the Houston community and the hard work of exceptional scientists, clinicians and staff of the Dan L. Duncan Cancer Center has created a strong center that is increasing our knowledge and understanding of cancer biology and delivering care to a broad spectrum of patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA125123-08S1
Application #
8804336
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2007-07-01
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
8
Fiscal Year
2014
Total Cost
$75,000
Indirect Cost
$27,076
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Badr, Hoda; Herbert, Krista; Bonnen, Mark D et al. (2018) Dyadic Coping in Patients Undergoing Radiotherapy for Head and Neck Cancer and Their Spouses. Front Psychol 9:1780
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
Ballester, Leomar Y; Lu, Guangrong; Zorofchian, Soheil et al. (2018) Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors. Acta Neuropathol Commun 6:85
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Gates, Leah A; Gu, Guowei; Chen, Yue et al. (2018) Proteomic profiling identifies key coactivators utilized by mutant ER? proteins as potential new therapeutic targets. Oncogene 37:4581-4598
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
Qin, Liying; Sankaran, Banumathi; Aminzai, Sahar et al. (2018) Structural basis for selective inhibition of human PKG I? by the balanol-like compound N46. J Biol Chem 293:10985-10992
Shi, Xiangguo; Kitano, Ayumi; Jiang, Yajian et al. (2018) Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells. Exp Hematol 64:33-44.e5
Disney-Hogg, Linden; Cornish, Alex J; Sud, Amit et al. (2018) Impact of atopy on risk of glioma: a Mendelian randomisation study. BMC Med 16:42

Showing the most recent 10 out of 991 publications